Fixed combination therapies in COPD - Effect on quality of life

International Journal of COPD

Volumn 2, Issue 4, 2007, Pages 551-557

  Groneberg Kloft, Beatrix ^a,b   Fischer, Axel ^b   Welte, Tobias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Combination therapy; COPD; Corticoid; Corticosteroid; Steroid

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; SALMETEROL; STEROID;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; MONOTHERAPY; MORTALITY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

EID: 38049116076     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Balter MS, La Forge J, Low DE, et al. 2003. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J, 10 (Suppl B):3B-32B.
2. Boschetto P, Quintavalle S, Miotto D, et al. 2006. Chronic obstructive pulmonary disease (COPD) and occupational exposures. J Occup Med Toxicol, 1: 11.
3. Calverley PM, Anderson JA, Celli B, et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775-89.
4. Calverley PM, Boonsawat W, Cseke Z, et al. 2003b. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22:912-9.
5. Calverley P, Pauwels R, Vestbo J, et al. 2003a. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361:449-56.
6. Calverley P, Walker P. 2003. Chronic obstructive pulmonary disease. Lancet, 362:1053-61.
7. Celli BR, Cote CG, Marin JM, et al. 2004. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 350:1005-12.
8. Celli BR, MacNee W 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
9. Fabbri L, Caramori G, Beghe B, et al. 1998. Chronic obstructive pulmonary disease international guidelines. Curr Opin Pulm Med, 4:76-84.
10. Fletcher C, Peto R. 1977. The natural history of chronic airflow obstruction. BMJ, 1:1645-8.
11. Groneberg-Kloft B, Kraus T, van Mark A, et al. 2006. Analysing the causes of chronic cough: Relation to diesel exhaust, ozone, nitrogen oxides, sulphur oxides and other environmental factors. J Occup Med Toxicol, 1:6.
12. Hajiro T, Nishimura K, Tsukino M, et al. 1998. Comparison of discriminative properties among disease-specific questionnaires for measuring health related quality of life in patients with chronic obstructive pulmonary disease. Am JRespir Crit Care Med, 157:785-90.
13. Hanania NA, Darken P, Horstman D, et al. 2003. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest, 124:834-43.
14. Hansen-Flaschen JH. 2003. Update in pulmonary medicine. Ann Intern Med, 138:319-25.
15. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. 1992. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis, 145:1321-7.
16. Ketelaars CAJ, Schlosser MAG, Mostert R, et al. 1996. Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax, 51:39-43.
17. Mahler DA, Wire P, Horstman D, et al. 2002. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166:1084-91.
18. McSweeny AJ, Grant I, Heaton RK, et al. 1982. Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med, 142:473-8.
19. Murray CJ, Lopez AD. 1997a. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 349:1498-504.
20. Murray CJL, Lopez AD. 1997b. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 349:1436-42.
21. Murray CJL, Lopez AD. 1997c. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349:1269-76.
22. Murray CJL, Lopez AD, Mathers CD, Stein C. 2001. The Global Burden of Disease 2000 Project: global programme on evidence for health policy discussion. Geneva: WHO, paper number 36.
23. Nannini L, Cates CJ, Lasserson TJ, Poole P. 2004. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003794.
24. National Heart LaBI. 2002. NHLBI morbidity and mortality chartbook. Bethesda: US Department of Health and Human Services, Public Health Service.
25. Pauwels RA, Buist AS, Calverley PM, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 163:1256-76.
26. Peto R, Speizer FE, Cochrane AL et al. 1983. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis, 128:491-500.
27. Rennard S, Decramer M, Calverley PM, et al. 2002. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J, 20:799-805.
28. Siafakas NM, Vermeire P, Pride NB, et al. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Ear Respir J, 8:1398-420.
29. Society AT. 1987. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis, 136:225-44.
30. Soriano JB, Maier WC, Egger P, et al. 2000. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax, 55:789-94.
31. Szafranski W, Cukier A, Ramirez A, et al. 2003. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Ear Respir J, 21:74-81.
32. Welte T, Groneberg DA. 2006. Asthma and COPD. Exp Toxicol Pathol, 57S2:35-40.
33. Wouters EF, Postma DS, Fokkens B, et al. 2005. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax, 60:480-7.